Upload File

208692orig1s000 - food and drug administration of administration oral tablet rx/otc dispensed...

  • Home
  • Documents
  • 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
46
CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208692Orig1s000 CHEMISTRY REVIEW(S)

Upload: ngodien

Post on 30-May-2018

222 views

Category:

Documents


0 download

Report

TRANSCRIPT

Page 1: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

208692Orig1s000

CHEMISTRY REVIEW(S)

Page 2: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 3: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 4: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 5: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 6: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 7: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 8: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 9: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 10: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 11: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 12: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 13: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 14: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 15: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 16: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 17: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 18: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 19: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 20: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 21: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 22: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 23: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 24: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 25: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 26: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 27: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 28: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 29: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 30: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 31: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 32: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 33: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 34: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 35: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 36: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 37: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 38: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 39: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 40: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 41: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 42: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE

NDA 208692 Review 1

Drug Name/Dosage Form Cabozantinib (S)-maleate Strength 20mg, 40 mg, 60 mg Route of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable

SUBMISSION(S) REVIEWED DOCUMENT DATE DISCIPLINE(S) AFFECTED

Quality Review Team

DISCIPLINE REVIEWER BRANCH/DIVISION Drug Substance Xiang Wang Drug Product Xiang Wang

Process Ying Zhang Microbiology N/A

Facility Laura Fontan Biopharmaceutics Fang Wu

Regulatory Business Process Manager

Rabiya Laiq Kristine Leahy

Application Technical Lead Xiao Chen Laboratory (OTR) N/A

ORA Lead Paul Perdue Environmental Assessment (EA) Raanan Bloom

 

 

 

 

 

 

 

Page 43: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 44: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 45: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE
Page 46: 208692Orig1s000 - Food and Drug Administration of Administration Oral Tablet Rx/OTC Dispensed Applicant Exelixis, Inc. US agent, if applicable SUBMISSION(S) REVIEWED DOCUMENT DATE

---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signedelectronically and this page is the manifestation of the electronicsignature.---------------------------------------------------------------------------------------------------------/s/----------------------------------------------------

ROBYN S JORDON05/06/2016

Reference ID: 3927858


Lecture 10sco.h-its.org/exelixis/web/teaching/lectures/lecture10.pdf · 2013. 11. 15. · Lecture 15: Wrap-up. Phylogenetic Inference so far ... TBR: Tree Bisection and Reconnection

208692Orig1s000 - Food and Drug Administration...Cabozantinib will be given to patients once daily orally (tablet) at 60 mg. Cabozantinib is a kinase inhibitor with activity against

AACR-Exelixis Renal Cell Carcinoma Research Fellowship...AACR-Exelixis Renal Cell Carcinoma Research Fellowship 2021 Program Guidelines and Application Instructions American Association

Lecture 10 - sco.h-its.orgsco.h-its.org/exelixis/web/teaching/lectures2014/lecture10.pdf · Lecture 10. Programming Practical & Seminar ... light 5/40 10/40 15/40 dark 15/40 5/40

Data Administration & Database Administration

Network administration Network administration

LNBI 3745 - Using Treemaps to Visualize Phylogenetic Treessco.h-its.org/exelixis/pubs/ISBMDA2005.pdf · Using Treemaps to Visualize Phylogenetic Trees, Adam Arvelakis 1,2, Martin

Exelixis, Inc

Lecture 13 - HITS gGmbHsco.h-its.org/exelixis/web/teaching/lectures14_15/lecture13.pdf · Units of Evolution: The Gene Genes are inherited from generation → generation Inheritance

CHMP assessment report...CHMP assessment report EMA/664123/2016 Page 7/119 1. Background information on the procedure 1.1. Submission of the dossier The applicant Exelixis International

EXELIXIS GROUP - Hon. Consulate of the Republic of Kenya ...trademission.kenyagreece.com/2013/files/2013/08/exelixis-group-pro… · EXELIXIS S.A. enters MDx & ART markets in GR,

High Performance Computing Lecture 2 - HITS gGmbHsco.h-its.org/exelixis/web/teaching/practical14_15/... · 2014-10-24 · Alexandros Stamatakis, WS 2008/2009 String Functions C has

Lecture 9 - HITS gGmbHsco.h-its.org/exelixis/web/teaching/lectures/lecture9.pdf · 2013-11-15 · Plan for next lectures Today: Phylogenetic search algorithms Lecture 10 (Kassian):

Tree of Life brochure - HITS gGmbHsco.h-its.org/exelixis/resource/doc/atol.pdf · University of California Davis Pam Soltis, University of Florida James Staley, University of Washington

Bacterial Communities in Women with Bacterial …sco.h-its.org/exelixis/web/teaching/seminar2015/Example.pdf · Bacterial Communities in Women with Bacterial Vaginosis: High Resolution

Patient Controlled Analgesia · • Administration – wrong set-up • Administration – wrong dose • Administration – wrong drug • Administration – wrong solution • Administration

208692Orig1s000 - Food and Drug Administration › drugsatfda_docs › nda › ... · Regulatory Project Manager Rajesh Venugopal/Christy Cottrell ... per IVRS]. Other efficacy endpoints

Hybrid Parallelization of the MrBayes & RAxML ... › exelixis › resource › doc › Phylo100225.pdf · 3 SAN DIEGO SUPERCOMPUTER CENTER at the UNIVERSITY OF CALIFORNIA, SAN DIEGO

RAxML Manual.pdf - HITS gGmbHsco.h-its.org/exelixis/resource/download/NewManual.pdf · About RAxML II. Getting Help III. RAxML Web-servers and GUI IV. Downloading RAxML ... or to

Exelixis v. Kappos

Introduction to population genetics & evolution - HITS gGmbHsco.h-its.org/exelixis/web/teaching/lectures/lecture13.pdf · What is evolution In a broad sense evolution = change over

sco.h-its.orgsco.h-its.org/exelixis/pubs/dissFernando.pdf · Die dritte Methode wird SEV (Subtree Equality Vectors) genannt und reduziert den Speicherbedarf nahezu proportional zum

PATIENT AUTHORIZATION FORM · 2019-07-19 · themselves my personal health information relevant to my treatment with Exelixis products (my PHI) for purposes of (1) providing the services

Exelixis and Ipsen Financial Community & Media Briefing€¦ · Exelixis and Ipsen Financial Community & Media Briefing ... (Child-Pugh score [C-P] A) ... Exelixis and Ipsen Financial

Introduction to Bioinformatics for Computer Scientistssco.h-its.org/exelixis/web/teaching/lectures14_15/lecture1.pdf · Model Organism A species that is extensively studied/sequenced

Maketa Geologikis Exelixis Gis

Exelixis - Helping Patients Recover Stronger and Live Longer

Exelixis Q1 2014 Financial Results

Lecture 4 - sco.h-its.orgsco.h-its.org/exelixis/web/teaching/lectures/lecture4_a.pdf · Amdahl's Law Scalability to large number of processors is limited by sequential part of program

Lecture 2 - Scientific Computing – HITS gGmbHsco.h-its.org/exelixis/web/teaching/lectures/lecture2.pdf · Slides at: . ... DNA is also know as the blueprint of life In a cell, the

TheFinancialEdge Administration Guide in Administration ... Payroll Administration

l’obésité et des maladies chroniques dans le continuum …€¦ · • Recherche Clinique (comme chercheur principal): ... cancer thyroïde), Exelixis (cancer thyroïde), Groupe

UNIT - III · 2020. 6. 10. · Administration Administration Administration Administration Administration Administration Administration Administration Local Government and Administration

Exelixis and Ipsen Financial Community & Media Briefing · Cabozantinib plus Nivolumab Phase 1 Results Review Sumanta Pal, M.D., City of Hope Panel Discussion (Moderated by Gisela

Sport Administration: Administration